Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine),Data Published in Pain Medicine ( CAMBRIDGE Mass.--(BUSINESS WIRE)--Jun ...)

Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine),Data Published in Pain Medicine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - Javelin Pharmaceuticals, Inc. (AMEX: JAV), a leading developer of novel products for pain control, today announced that its Phase 2 multi-dose study of Rylomine was published in Pain Medicine, the official journal of The American Academy of Pain Medicine. The article, entitled, "Analgesic Efficacy and Safety of Morphine-Chitosan Nasal Solution in Patients with Moderate to Severe Pain Following Orthopedic Surgery", was recently made available online and can found at the following link: http://www.blackwell-synergy.com/toc/pme/0/0?.

"Rylomine is one of three late stage drug development candidates in our pipeline that address large underserved markets for pain management. It employs a patented formulation of intranasal morphine in a simple disposable device that requires no programming or special patient education," said, Dr. Daniel B. Carr, CEO and CMO. "While still in development, Rylomine has potential to become the non-invasive approach of choice for administering intermittent doses of morphine for post-surgical pain in medically supervised settings. Morphine is the reference standard for treatment of post-surgical pain, as well as pain from trauma and diseases including cancer."

Top line data from the first of two pivotal post-surgical Phase 3 clinical trials of Javelin's Rylomine is anticipated this summer.

Orthopedic Surgeries

According to the United States Department of Health and Human Services, orthopedic operations make up approximately 10% (7.4 million) of the 73.4 million ambulatory and in-patient surgical procedures in the United States annually.

About Rylomine

Rylomine (intranasal morphine), is currently in Phase 3 development in the United States, for moderate-to-severe pain in supervised healthcare settings. It employs the patented and proprietary, Chysis(R) drug-delivery platform to adhere and regularize the kinet
'"/>

Page: 1 2 3
Related medicine technology :

1. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies

Post Your Comments:

(Date:7/11/2014)... Neurelis, Inc. ("Neurelis") today announced an agreement ... held by Biotie to purchase Neurelis, clearing the way ... diazepam) for pediatric and adult epilepsy patients who experience ... Biotie has advanced the development program for NRL-1 and ... work required for NDA submission to the FDA. Given ...

(Date:7/10/2014)... July 10, 2014 Breg, Inc., a premier ... launched the FreeRunner™ knee brace with new innovations ... patella mal-tracking return to active lifestyles. FreeRunner,s patent-pending ... braces, providing support when patients need it most, ... don,t. Patellofemoral issues are the most ...

(Date:7/10/2014)... , July 10, 2014 BC Technical, the ... MiE America , Inc., a leading provider of ... into a long-term agreement naming BC Technical as the ... MiE and BC Technical announced today ... to establish BC Technical as the service and systems ...

Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2 Neurelis Regains Rights to Intranasal Diazepam Program 3 Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2 BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2

[0] Neurelis Regains Rights to Intranasal Diazepam Program [0] Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome [0] BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service

... 20, 2011 Ann Arbor SPARK recently celebrated the conclusion ... and a reception. At the Ann Arbor SPARK Boot Camp ... Boot Camp" winner, based on the quality of its investor ... engagement though the Ann Arbor SPARK Business Accelerator. ...

... HYDERABAD, India, May 20, 2011 Neuland Laboratories Ltd., ... (APIs), complex intermediates, and contract research and manufacturing services ... results for the 2011 fiscal year (FY) ended March ... report that in fiscal year 2011, Neuland delivered on ...

Cached Medicine Technology:Brio Device Awarded Best of Ann Arbor SPARK's Boot Camp 2 Neuland Labs Reports Financial Results for Fiscal Year 2011 2

Brio Device Awarded Best of Ann Arbor SPARK's Boot Camp Neuland Labs Reports Financial Results for Fiscal Year 2011

(Date:7/13/2014)... 2014 A Xarelto lawsuit webpage ... to provide consumers with the most current information regarding ... the blood-thinning medication, as well as the growing ... around the country. The law firm is now offering ... from life-threatening internal bleeding and related complications while using ...

(Date:7/13/2014)... Hope Palliative & Hospice Care announced today that they ... Tamarack Senior Living Community in Palatine, IL. The group, called ... 3rd Wednesdays of every month. This group will begin ... at 55 S. Greeley St. Palatine, IL 60067. It ... cost for the group. , “A grief support group ...

(Date:7/13/2014)... Wa (PRWEB) July 13, 2014 According ... by Vkool.com, this is a comprehensive guide that features ... deal with KP (keratosis pilaris). This guide ... 1: What Is Keratosis Pilaris? , Chapter 2: ... I Know If I Have KP? , Chapter ...

(Date:7/12/2014)... Recently, Fadhits.com, a well-known wedding dress manufacturer and ... graduation dresses to its product line. In addition, the ... It wants to bring more benefits for its loyal fans. ... discounted prices, up to 72% off. , As a leader ... Its online shop is a good place for ladies who ...

(Date:7/12/2014)... The Passenger Information System market is ... $20,341.36 million by 2019, at an expected CAGR of ... The public transport infrastructure in North America is well ... almost every corner of the region. The growing ridership ... transport service providers are driving the North American Passenger ...

Breaking Medicine News(10 mins):Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2 Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3 Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4 Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2 Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2 Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3 Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2 Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2 Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3 Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4

[0] Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation [0] Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community [0] Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com [0] New Collection of Long Graduation Dresses Revealed by Fadhits.com [0] North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor

... Yingxia,International, Inc. (OTC Bulletin Board: CYXI) ("China Yingxia" ... industry engaged in the,development, manufacture and distribution of ... in the People,s Republic,of China ("PRC"), today reported ... 31, 2008., First Quarter 2008 Highlights, ...

... goal of tailoring cancer treatment for each individual, researchers ... suggesting a simple blood test can help doctors more ... cancer. , It can take several weeks and sometimes ... working because it can take that long to observe ...

... protein called IGF-1R in patients with gastrointestinal stromal tumors ... responsive to the drug imatinib mesylate (known as Gleevec), ... the Fox Chase Cancer Center in Philadelphia. Preliminary ... might respond well to agents in development for treatment-resistant ...

... Digital Power,Corporation (Amex: DPW ) (herein "Digital Power") ... March 31, 2008., Digital Power reported revenue of ... of 15.6% from $2,742,000 for the same quarter,last year. ... of 2008 was,reported, compared to an operating profit of ...

... 15 /Xinhua-PRNewswire-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC Bulletin ... company with its principal operations,in the People,s Republic ... quarter ended March 31, 2008, the Company,s third ... A 10QSB Form was filed for the quarter,with ...

... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today ... Vice President, Quality. He will have,responsibilities in the ... manufacturing operations and preclinical / clinical,product candidates. Mr. ... at Telik, Inc. in Palo Alto, California, where ...

China Yingxia International, Inc. Reports First Quarter 2008 Results Study suggests blood test can help improve treatment outcomes for breast cancer patients Protein predicts Gleevec resistance in gastrointestinal tumors Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality

The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....

Inquire...

... Immunosorbent Assays(ELISA) is intended for the detection ... Measles Rubeola) virus in human sera. Individual ... determination of immune status. Paired sera, acute ... or a significant rise in antibody as ...

Measles IgM ELISA test is an enzyme linked immunosorbent assay (ELISA) for the detection of IgG class antibodies to Measles (Rubeola) in human serum or plasma....

Medicine Products:

Pach IV Pachymeter RIDASCREEN Anti-Measles Virus IgM Assay Captia Measles IgG Measles (Rubeola) IgG ELISA